D&B Business Directory
Genmab A/S
Limited liability company Parent
Genmab A/S
Genmab analyzes genomes in its lab. The biotech company creates and develops human antibodies to attack cancer, autoimmune, and inflammatory diseases. It holds a portfolio of candidates in stages of development ranging from pre-clinical to late-stage trials. Its first marketed product is Ofatumumab, for the treatment of a type of chronic lymphocytic leukemia. Genmab is also working on Daratumumab, a monoclonal antibody that holds the potential ...
Read More
to kill multiple myeloma cells. The company has licensing and development partnerships with several international pharmaceutical and biotech companies. Genmab was founded in 1999.
Read Less
Jan van de Winkel   See more contacts
Kalvebod Brygge 43 1560, København V, Hovedstaden Denmark See other locations
$1.61 billion
88.43% 119.67% $3,358 DEC
1998 2007
OMX Copenhagen:GMAB
Stay on top of your Business Credit File
Get full access to view your D&B business credit file now for just $39/month!
View D&B Scores & Ratings
Get in Touch with 13 Principals*
A D&B Hoovers Subscription is your foot in the door to Genmab A/S contact information.
  • Jan van de Winkel
    Managing Director
  • Pernille Lyngvold Erenbjerg
    Vice Chairperson
  • Paolo Augusto Paoletti
    Board Member
  • Peter Storm Kristensen
    Staff representative on the board
D&B Hoovers Logo

Dynamic search and list-building capabilities

Real-time trigger alerts

Comprehensive company profiles

Valuable research and technology reports

Financial Statements
Dun & Bradstreet collects private company financials for more than 23 million companies worldwide. Find out more.
Financial data as of December 31, 2020 (12 month period) in USD
Annual Revenue 2020
$1.61 billion USD
1 USD = 6.2953 DKK